Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Aims For 14 New Blockbuster Drugs By End Of 2017

This article was originally published in The Pink Sheet Daily

Executive Summary

At an investor day presentation Nov. 8, Novartis discussed a pipeline expected to yield 18 regulatory decisions over the next 24 months. The Swiss pharma currently has 139 ongoing pipeline projects, including 73 NMEs.

Advertisement

Related Content

As Sun Sets On Gleevec, Novartis Looks To New Horizons In Oncology
Afinitor's Pancreatic Tumor Indication Limited To Progressive Disease

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel